Intuitive Surgical, Inc. (NASDAQ:ISRG) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Intuitive Surgical, with 22 buy, eight hold and one sell rating among 31 firms. The average 12-month price target is $508.68.
• Intuitive Surgical’s latest quarter exceeded expectations, with EPS of $2.80 versus $2.48 expected and revenue of $2.89 billion, up 18.4% year over year.
• Shares opened at $393.33 after rising 2.6%, while insiders sold 12,370 shares worth approximately $4.9 million over the past three months; institutional investors own 83.64% of the stock.

Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report) has been given a consensus rating of "Moderate Buy" by the thirty-one ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and twenty-two have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $508.6830.

Several research analysts have recently issued reports on ISRG shares. TD Cowen cut Intuitive Surgical from a "buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Truist Financial lowered their price target on Intuitive Surgical from $580.00 to $510.00 and set a "buy" rating for the company in a report on Thursday, July 16th. Oppenheimer upgraded shares of Intuitive Surgical from a "market perform" rating to an "outperform" rating and set a $500.00 target price for the company in a report on Wednesday, August 12th. Stifel Nicolaus dropped their target price on shares of Intuitive Surgical from $670.00 to $550.00 and set a "buy" rating on the stock in a research report on Friday, July 17th. Finally, Leerink Partners cut their price target on shares of Intuitive Surgical from $573.00 to $454.00 and set an "outperform" rating on the stock in a research note on Friday, July 17th.

Intuitive Surgical Trading Up 2.6%

Shares of ISRG opened at $393.33 on Friday. Intuitive Surgical has a twelve month low of $328.57 and a twelve month high of $603.88. The firm's fifty day simple moving average is $372.69 and its 200-day simple moving average is $419.71. The firm has a market capitalization of $138.96 billion, a price-to-earnings ratio of 45.06, a PEG ratio of 2.89 and a beta of 1.47.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $2.48 by $0.32. The firm had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The company's revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.81 earnings per share. On average, analysts predict that Intuitive Surgical will post 8.87 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the transaction, the executive vice president directly owned 5,320 shares in the company, valued at approximately $2,016,280. This trade represents a 6.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary S. Guthart sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $400.00, for a total value of $4,000,000.00. Following the completion of the transaction, the director directly owned 1,245,679 shares in the company, valued at approximately $498,271,600. The trade was a 0.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,370 shares of company stock worth $4,891,989 in the last three months. Company insiders own 0.60% of the company's stock.

Hedge Funds Weigh In On Intuitive Surgical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Motiv8 Investments LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter worth $34,000. Main Street Group LTD acquired a new position in shares of Intuitive Surgical during the first quarter worth about $30,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Intuitive Surgical during the fourth quarter worth about $39,000. Vermillion Wealth Management Inc. raised its holdings in Intuitive Surgical by 58.1% during the first quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 25 shares in the last quarter. Finally, Evergreen Advisors LLC purchased a new position in Intuitive Surgical during the first quarter worth about $35,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc is a medical technology company that develops and manufactures robotic-assisted surgical systems and related products. Its technology is designed to support surgeons during minimally invasive procedures by providing enhanced visualization, instrument control and dexterity.

The company's principal product is the da Vinci Surgical System, which is used across a range of specialties, including general surgery, urology, gynecology, cardiothoracic surgery and other procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.